CpG plus radiotherapy: A review of preclinical works leading to clinical trial

Frontiers in Oncology

Volumn 2 AUG, Issue , 2012, Pages

  Mason, Kathy A ^a   Hunter, Nancy R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CpG; Immunotherapy; Oligodeoxynucleotides; Radiotherapy

Indexed keywords

OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CPG ISLAND; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IRRADIATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY;

EID: 84871380037     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00101     Document Type: Short Survey

References (59)

1. Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J. P., Delaloge, S., Andre, F., Tursz, T., Kroemer, G., and Zitvogel, L. (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47-59.
2. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059.
3. Baines, J., and Celis, E. (2003). Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res. 9, 2693-2700.
4. Blazar, B. R., Krieg, A. M., and Taylor, P. A. (2001). Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 98, 1217-1225.
5. Brody, J., Kohrt, H., Marabelle, A., and Levy, R. (2011). Active and passive immunotherapy for lymphoma: proving principles and improving results. J. Clin. Oncol. 29, 1864-1875.
6. Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., and Levy, R. (2010). In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 28, 4324-4332.
7. Cerkovnik, P., Jezersek Novakovic, B., Stegel, V., and Novakovic, S. (2009). Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. Innate Immun. 15, 313-321.
8. Cerkovnik, P., Novakovic, B. J., Stegel, V., and Novakovic, S. (2010). Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol. 11, 45. doi: 10.1186/1471-2172-11-45
9. Chamoto, K., Takeshima, T., Wakita, D., Ohkuri, T., Ashino, S., Omatsu, T., Shirato, H., Kitamura, H., Togashi, Y., and Nishimura, T. (2009). Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio-and immuno-resistant lung carcinoma cells. Cancer Sci. 100, 934-939.
10. Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Adhami, M. A., Krieg, A. M., Cameron, D. W., and Heathcote, J. (2004a). CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24, 693-701.
11. Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., and Cameron, D. W. (2004b). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22, 3136-3143.
12. Demaria, S., Bhardwaj, N., McBride, W. H., and Formenti, S. C. (2005). Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63, 655-666.
13. den Brok, M. H., Sutmuller, R. P., Nierkens, S., Bennink, E. J., Toonen, L. W., Figdor, C. G., Ruers, T. J., and Adema, G. J. (2006). Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 66, 7285-7292.
14. Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., and Demaria, S. (2009). Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379-5388.
15. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998.
16. Formenti, S. C. (2010). Immunological aspects of local radiotherapy: clinical relevance. Discov. Med. 9, 119-124.
17. Formenti, S. C., and Demaria, S. (2008). Effects of chemoradiation on tumor-host interactions: the immunologic side. J. Clin. Oncol. 26, 1562-1563; author reply 1563.
18. Goldstein, M. J., Varghese, B., Brody, J. D., Rajapaksa, R., Kohrt, H., Czerwinski, D. K., Levy, S., and Levy, R. (2011). A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117, 118-127.
19. Hart, J. P., Carpenter, J., Patel, N., Valdecanas, D., Mason, K., and Milas, L. (2008). CpG Oligodeoxynucleotides (CpG ODN) immunotherapy enhances tumor radioresponse: systemic effects and mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 72, S168.
20. Haynes, N. M., and Smyth, M. J. (2012). Immunotherapeutic strategies as adjuncts to local radiotherapy. Immunotherapy 4, 129-131.
21. Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdorfer, B., Krug, A., Rothenfusser, S., Endres, S., and Hartmann, G. (2002). Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169, 3892-3899.
22. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
23. Houot, R., and Levy, R. (2009). T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113, 3546-3552.
24. Jahrsdorfer, B., and Weiner, G. J. (2008). CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 3, 27-32.
25. Kawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., and Hammerling, G. J. (2001). NK-and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167, 5247-5253.
26. Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, B., Shah, S., Hoppe, R. T., and Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119, 355-363.
27. Koski, G. K., and Czerniecki, B. J. (2005). Combining innate immunity with radiation therapy for cancer treatment. Clin. Cancer Res. 11, 7-11.
28. Krieg, A. M. (2001). From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 11, 181-188.
29. Krieg, A. M. (2004). Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6, 88-95.
30. Krieg, A. M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484.
31. Krieg, A. M. (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161-167.
32. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
33. Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. M., and Levy, R. (2007). Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179, 2493-2500.
34. Lonsdorf, A. S., Kuekrek, H., Stern, B. V., Boehm, B. O., Lehmann, P. V., and Tary-Lehmann, M. (2003). Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol. 171, 3941-3946.
35. Lugade, A., Moran, J., Gerber, S., Rose, R., Frelinger, J., and Lord, E. (2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516-7523.
36. Mason, K. A., Ariga, H., Neal, R., Valdecanas, D., Hunter, N., Krieg, A. M., Whisnant, J. K., and Milas, L. (2005). Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. 11, 361-369.
37. Matsumura, S., and Demaria, S. (2010). Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat. Res. 173, 418-425.
38. Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., and Demaria, S. (2008). Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099-3107.
39. Meng, Y., Carpentier, A. F., Chen, L., Boisserie, G., Simon, J. M., Mazeron, J. J., and Delattre, J. Y. (2005). Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 116, 992-997.
40. Mihich, E., and Fefer, A. (1983). Biological Response Modifiers: Subcommittee Report. Monograph No. 63. Washington, DC: National Cancer Institute.
41. Milas, L. (1980). "Combination of immunotherapy and radiotherapy in the treatment of malignant tumors," in Progress in Radio-Oncology, eds K. Karcher, H. Kogeinic, and H. Myer (New York: Thieme-Stratton, Inc.), 58-69.
42. Milas, L., Gutterman, J., Basic, I., and Withers, H. (1974a). Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum. Int. J. Cancer 14, 439.
43. Milas, L., Hunter, N., Basic, I., and Withers, R. (1974b). Complete regressions of an established murine fibrosarcoma induced by systemic application of Corynebacterium granulosum. Cancer Res. 34, 2470-2475.
44. Milas, L., Hunter, N., and Withers, H. (1975a). Combination of local irradiation with systemic application of anaerobic corynebacteria in therapy of a murine fibrosarcoma. Cancer Res. 35, 1274.
45. Milas, L., Withers, H., and Hunter, N. (1975b). C. Granulosum-and C. Parvum-induced augmentation of the radiocurability of a murine fibrosarcoma. Proc. Am. Assoc. Cancer Res. 16, 154.
46. Milas, L., Mason, K., Ariga, H., Hunter, N., Neal, R., Valdecanas, D., Krieg, A. M., and Whisnant, J. (2004). CpG Oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 64, 5074-5077.
47. Milas, L., Mason, K., and Withers, H. R. (1976). Therapy of spontaneous pulmonary metastases of a murine mammary carcinoma with anaerobic corynebacteria. Cancer Immunol. Immunother. 1, 233.
48. Milas, L., and Scott, M. T. (1978). Antitumor activity of Corynebacterium parvum. Adv. Cancer Res. 26, 257-306.
49. Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., and Kroemer, G. (2007). Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848-1850.
50. Shah, J. A., Darrah, P. A., Ambrozak, D. R., Turon, T. N., Mendez, S., Kirman, J., Wu, C. Y., Glaichenhaus, N., and Seder, R. A. (2003). Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198, 281-291.
51. Shiao, S. L., and Coussens, L. M. (2010). The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 15, 411-421.
52. Stone, H. B., and Milas, L. (1978). Modification of radiation responses of murine tumors by misonidazole (Ro 07-0582), host immune capability, and Corynebacterium parvum. J. Natl. Cancer Inst. 60, 887-893.
53. Suit, H. D., Sedalcek, R., Silobrcic, V., and Linggood, R. M. (1976). Radiation therapy and Corynebacterium parvum in the treatment of murine tumors. Cancer 37, 2573.
54. Teitz-Tennenbaum, S., Li, Q., Okuyama, R., Davis, M. A., Sun, R., Whitfield, J., Knibbs, R. N., Stoolman, L. M., and Chang, A. E. (2008). Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J. Immunother. 31, 345-358.
55. Tokunaga, T., Yamamoto, T., and Yamamoto, S. (1999). How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 52, 1-11.
56. Uhlmann, E., and Vollmer, J. (2003). Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Dev. 6, 204-217.
57. Weigel, B. J., Rodeberg, D. A., Krieg, A. M., and Blazar, B. R. (2003). CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9, 3105-3114.
58. Yron, I., Weiss, D. W., Robinson, E., Cohen, D., Adelberg, M. G., Mekori, T., and Haber, M. (1973). Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors. Natl. Cancer Inst. Monogr. 39, 33-55.
59. Yuan, S., Qiao, T., and Chen, W. (2011). CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother. Radiopharm. 26, 203-208.